Company Overview
Vision and Mission
Leadership Team
Board of Directors
ESG
The United Nations Global Compact
Contact Us
Pipeline and Major Products
Discovery
Manufacturing
Partners
Press Releases
Media Coverage
Awards
Presentations and Webcasts
Announcements and Circulars
Financial Reports and Listing Documents
Analyst Coverage
Corporate Governance
Events Calendar
IR Contact and Email Alert
Job Opportunities
Ian Woo Joins Everest Medicines as President and Chief Financial Officer; Named Managing Director of C-Bridge Capital
Tetraphase Pharmaceuticals Announces Everest Medicines’ Submission of an Investigational New Drug Application for Eravacycline in Complicated Intra-Abdominal Infection to the China Food and Drug Admin
Tetraphase Pharmaceuticals Enters Into Exclusive Development and Commercialization Agreement with Everest Medicines for Eravacycline in China.
Arena eligible to receive up to $224M, including upfront and milestone payments, in addition to royalties.
C-Bridge Capital specializes in the growing Chinese health care market and is using its expertise to identify emerging industry leaders and bring global innovation into China.